Investor Profile: Cormorant Asset Management — Thesis, Cheque Size & How to Apply

Cormorant Asset Management is a Boston-based healthcare investment firm, and Cormorant Asset Management funding reaches founders through two routes: its public-market healthcare funds and its private healthcare funds. Founded by Bihua Chen, the firm specialises in innovative biotechnology, medical technology and life science companies, and it is one of the most active crossover investors in the sector, backing companies before and after they go public.

Investment thesis

Cormorant invests globally in the healthcare sector, with a dedicated focus on biotechnology and life sciences. Its model blends public equity investing, including large positions in listed biotech companies, with private investments through its private healthcare funds, allowing it to support companies across the crossover from private rounds into initial public offerings and beyond.

Sectors and stages

The firm invests across biotechnology, medical technology and life sciences, in both public and private companies. Third-party tracking puts its portfolio at more than 170 companies, and its public filings show positions spanning immunology, oncology, neurology, genetic disease and medical devices. It is best understood as a growth and crossover investor rather than a seed-stage venture fund.

Fund size and cheque size

Cormorant's discretionary assets under management totalled $4,022,479,936 across 14 clients, according to its Form ADV dated 30 March 2024. Its typical cheque size is not publicly disclosed, and because much of its activity is public-market investing, there is no published venture cheque range. Its private healthcare vehicles include the Cormorant Private Healthcare Fund III, named in its regulatory filings.

Notable portfolio

Public positions disclosed in Cormorant's filings include MoonLake Immunotherapeutics, its largest reported 13F holding in recent filings; Parabilis Medicines, which became a top portfolio holding in 2026; BridgeBio Pharma; Olema Pharmaceuticals; Biomea Fusion; Cabaletta Bio; Corbus Pharmaceuticals; Bright Minds Biosciences; and iBio. Third-party tracking also credits the firm with 46 unicorn portfolio companies, reflecting its long crossover track record.

Partners and team

Bihua Chen is the founder of Cormorant Asset Management and serves as managing member of its general partner entities. Before founding Cormorant, she managed a healthcare-focused account as a sub-adviser to a multi-strategy hedge fund in New York. She holds a BS in genetics and genetic engineering from Fudan University, an MS in molecular biology from Cornell Medical College's Graduate School of Biomedical Science, and an MBA from the Wharton School. The firm is based at 200 Clarendon Street, Boston, Massachusetts.

Programmes and perks

No public accelerator, credits or perks programme run by Cormorant was found in the sources we read. It is an investment manager for pooled vehicles, not a founder programme operator, so founders should not expect structured perks or a demo day route.

How to apply for funding

Cormorant publishes no open application form or public submission portal that we could verify, and no official public website for the firm was located during research. Founders seeking private investment should therefore approach through an existing investor, adviser or banker who can introduce them to the firm, with a financing round already taking shape, since Cormorant typically joins syndicates and crossover rounds rather than sourcing cold pitches.